How to Find Information About Craig Wheeler's Appointment to the Apellis Pharmaceuticals Board

Craig Wheeler joined the Apellis Pharmaceuticals board of directors in April 2025

Craig Wheeler was appointed to the board of directors of Apellis Pharmaceuticals in April 2025. Apellis is a publicly traded biopharmaceutical company that develops treatments for rare diseases, particularly those affecting the eye, ear, and kidney. Board appointments at public companies are disclosed through regulatory filings with the Securities and Exchange Commission (SEC) and announced through official company press releases. These appointments reflect a company's strategy for adding expertise, industry experience, or specific skill sets to guide decision-making at the executive level.

If you are an investor, employee, or stakeholder tracking this appointment, you can find official details through Apellis' investor relations website, SEC filings, and company press releases. Understanding where to look and what information is typically disclosed will help you understand the company's direction and governance structure.

Key Takeaways

• Craig Wheeler joined the Apellis Pharmaceuticals board of directors in April 2025 as disclosed through SEC filings and company announcements.
• Official information about the appointment is available through Apellis' investor relations website, SEC EDGAR database, and company press releases.
• Board appointments at pharmaceutical companies are disclosed through Form 8-K filings within four business days and detailed in the company's annual proxy statement.
• New board members at pharmaceutical companies typically bring expertise in clinical development, regulatory affairs, rare disease markets, or business strategy.
• Investors and stakeholders monitor board changes because they signal company priorities and reflect governance quality.

Where to find the official announcement and SEC filings

The most reliable source for details about Craig Wheeler's appointment is Apellis Pharmaceuticals' official investor relations website. Public companies are required to disclose board changes through SEC filings, including Form 8-K (current report of material events) filed within four business days of the appointment, and the company's proxy statement filed annually before the shareholder meeting.

You can access SEC filings through the EDGAR database at sec.gov, where you can search by company name or ticker symbol. Enter "Apellis Pharmaceuticals" to find all filings, then look for Form 8-K documents dated around April 2025 that reference board appointments. Apellis' official press releases about board appointments are also published on their corporate website under the news or press release section, usually with the director's background and relevant experience included.

What information is included in a board appointment disclosure

When a public company appoints a new board member, the announcement typically includes the director's professional background, relevant experience, any committee assignments, and a statement from company leadership explaining why the appointment strengthens the board. The SEC Form 8-K filing includes basic appointment details, while the company's proxy statement provides more comprehensive biographical information.

The annual proxy statement—filed before the shareholder meeting—lists all board members, their age, tenure, areas of expertise, other board positions they hold, and any potential conflicts of interest. This document gives investors a complete picture of board composition and is available on both the SEC website and the company's investor relations page.

Why board appointments matter at pharmaceutical companies

Board members at a pharmaceutical company like Apellis oversee strategy, clinical development progress, regulatory matters, and financial performance. A new board appointment often signals that the company is seeking specific expertise—such as experience with FDA approval processes, rare disease markets, international expansion, or particular therapeutic areas.

For investors and employees, board changes can indicate the company's priorities and the challenges or opportunities it expects ahead. A board member with deep experience in a specific regulatory environment or disease area may suggest the company is preparing for significant milestones, such as clinical trial results, regulatory submissions, or market expansion. This information helps stakeholders understand company direction and evaluate leadership quality.

How board composition works at public pharmaceutical companies

Public pharmaceutical companies maintain boards that typically include between 7 and 12 members with diverse backgrounds: industry veterans, clinical experts, business leaders, regulatory specialists, and sometimes patient advocates. Board members meet regularly to oversee company operations, strategy, and governance.

Most boards organize into committees that handle specific areas of oversight—such as audit, compensation, clinical or scientific matters, and governance. New appointments often fill vacancies created by retirements or resignations, or expand the board to add needed expertise during periods of significant company activity, such as late-stage clinical trials or regulatory reviews.

What investors and stakeholders look for in board changes

Board appointments are monitored by investors, analysts, employees, and patient advocates because they reflect company strategy and governance quality. A director with deep experience in a particular area signals that the company is preparing for specific challenges or opportunities. Board independence, diversity of expertise, and relevant industry experience are all factors investors consider when evaluating a company's leadership.

Shareholders also assess whether new board members bring fresh perspectives or reinforce existing expertise. Board changes are one of several factors investors consider when evaluating a company's overall governance structure, decision-making quality, and strategic direction. Tracking these changes helps stakeholders stay informed about company priorities and leadership decisions.

How to stay informed about future board changes at Apellis

To receive updates about board appointments and other material company news, you can subscribe to Apellis' investor relations email alerts through their corporate website. The company typically announces board changes through press releases and SEC filings, both of which are publicly available.

You can also monitor the SEC EDGAR database by setting up alerts for Apellis Pharmaceuticals filings, or check the company's investor relations page regularly for news and announcements. Financial news websites and investor relations platforms often cover significant board appointments at public companies as well.

Frequently Asked Questions

Where can I read the official announcement of Craig Wheeler's board appointment?

Apellis Pharmaceuticals' official press release is available on their corporate website under the news or press releases section. You can also find the SEC Form 8-K filing through the EDGAR database at sec.gov by searching for Apellis Pharmaceuticals and looking for filings dated around April 2025 that reference board appointments.

What does it mean when a pharmaceutical company appoints a new board member?

A new board appointment typically signals that the company is seeking specific expertise to guide strategy and oversight. The appointment may indicate the company is preparing for clinical milestones, regulatory submissions, market expansion, or other strategic priorities. It reflects the company's assessment of what skills and experience the board needs.

How do I find information about all of Apellis' current board members?

The company's annual proxy statement lists all board members, their backgrounds, expertise, and tenure. This document is available on the SEC website and Apellis' investor relations page. You can also find board information on the company's corporate website under the leadership or governance section.

When are board appointments publicly disclosed?

Public companies must file a Form 8-K with the SEC within four business days of a board appointment. The appointment is also typically announced through a company press release. Complete biographical information appears in the company's annual proxy statement filed before the shareholder meeting.